Title:
SYSTEMS AND METHODS FOR CELL-BASED IMMUNOTHERAPIES CROSS-REFERENCE
Document Type and Number:
WIPO Patent Application WO/2023/093763
Kind Code:
A1
Abstract:
Provided are systems and methods for immunotherapies. Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.
Inventors:
XU JING (CN)
GAO YANGBIN (CN)
YANG LUHAN (CN)
LI HUASHUN (CN)
LV YAQI (CN)
GAO YANGBIN (CN)
YANG LUHAN (CN)
LI HUASHUN (CN)
LV YAQI (CN)
Application Number:
PCT/CN2022/133745
Publication Date:
June 01, 2023
Filing Date:
November 23, 2022
Export Citation:
Assignee:
HANGZHOU QIHAN BIOTECHNOLOGY CO LTD (CN)
International Classes:
C12N5/074; A61K35/17; A61K35/545; A61K39/395; A61K45/06; A61P35/00; C12N5/0783; C12N5/0789
Domestic Patent References:
| WO2021223705A1 | 2021-11-11 |
Foreign References:
| CN111542594A | 2020-08-14 | |||
| CN113166232A | 2021-07-23 | |||
| US20210024959A1 | 2021-01-28 |
Other References:
ZHU，H.ET AL.: "Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity", BLOOD, vol. 135, no. 6, 6 February 2020 (2020-02-06), XP055967123, DOI: 10.1182/blood.2019000621
M CARLSTEN ET AL: "Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19", FRONTIERS IN IMMUNOLOGY, vol. 7, 22 March 2016 (2016-03-22), pages 1 - 9, XP002790265, DOI: 10.3389/fimmu.2016.00105
M CARLSTEN ET AL: "Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19", FRONTIERS IN IMMUNOLOGY, vol. 7, 22 March 2016 (2016-03-22), pages 1 - 9, XP002790265, DOI: 10.3389/fimmu.2016.00105
Attorney, Agent or Firm:
AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: